Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
Year: 2021
Type: article
Study design: Clinical Trial
Source: The Lancet Oncology
Authors: Saad Z Usmani, Hang Quach, Maria-Victoria Mateos, Ola Landgren, Xavier Leleu, David Siegel, Katja Weisel, Maria Gavriatopoulou, Albert Oriol, Neil Rabin, Ajay Nooka, Ming Qi, Meral Beksac, Andrzej Jakubowiak, Bifeng Ding, Anita Zahlten-Kumeli, Akeem Yusuf, Meletios Dimopoulos
Institutions: Levine Cancer Institute, The University of Melbourne, St Vincent's Hospital Melbourne, University of Miami, Sylvester Comprehensive Cancer Center, Inserm, Centre Hospitalier Universitaire de Poitiers, Hackensack University Medical Center, University Medical Center Hamburg-Eppendorf, National and Kapodistrian University of Athens, Josep Carreras Leukaemia Research Institute, Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, University College London Hospitals NHS Foundation Trust, University College London, Emory University, Winship Cancer Institute, Ankara University, University of Chicago Medical Center, Amgen (United States)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4200089360